{"title": "Development and Evaluation of A CRISPR-based Diagnostic For 2019-novel Coronavirus", "doi": "10.1101/2020.02.22.20025460", "citation_id": "2020.02.22.20025460v2", "date": "2020-02-25", "laguage": "en", "journal_title": "medRxiv", "first_page": "2020.02.22.20025460", "abstract": "<p>Background: The recent outbreak of infections by the 2019 novel coronavirus (2019-nCoV), the third zoonotic CoV has raised great public health concern. The demand for rapid and accurate diagnosis of this novel pathogen brought significant clinical and technological challenges. Currently, metagenomic next-generation sequencing (mNGS) and reverse-transcription PCR (RT-PCR) are the most widely used molecular diagnostics.\n\nMethods: 2019-nCoV infections were confirmed in 52 specimens by mNGS. Genomic information was analyzed and used for the design and development of an isothermal, CRISPR-based diagnostic for this novel virus. The diagnostic performance of CRISPR-nCoV was assessed and compared across three technology platforms (mNGS, RT-PCR and CRISPR). \n\nResults: 2019-nCoVs sequenced in our study were conserved with the Wuhan strain, and shared certain genetic similarity with SARS-CoV. A high degree of variation in the level of viral RNA was observed in clinical specimens. CRISPR-nCoV demonstrated a near single-copy sensitivity and great clinical sensitivity with a shorter turn-around time than RT-PCR.\n\nConclusion: CRISPR-nCoV presents as a promising diagnostic option for the emerging pathogen.</p>", "twitter_description": "Background: The recent outbreak of infections by the 2019 novel coronavirus (2019-nCoV), the third zoonotic CoV has raised great public health concern. The demand for rapid and accurate diagnosis of this novel pathogen brought significant clinical and technological challenges. Currently, metagenomic next-generation sequencing (mNGS) and reverse-transcription PCR (RT-PCR) are the most widely used molecular diagnostics. Methods: 2019-nCoV infections were confirmed in 52 specimens by mNGS. Genomic information was analyzed and used for the design and development of an isothermal, CRISPR-based diagnostic for this novel virus. The diagnostic performance of CRISPR-nCoV was assessed and compared across three technology platforms (mNGS, RT-PCR and CRISPR). Results: 2019-nCoVs sequenced in our study were conserved with the Wuhan strain, and shared certain genetic similarity with SARS-CoV. A high degree of variation in the level of viral RNA was observed in clinical specimens. CRISPR-nCoV demonstrated a near single-copy sensitivity and great clinical sensitivity with a shorter turn-around time than RT-PCR. Conclusion: CRISPR-nCoV presents as a promising diagnostic option for the emerging pathogen.\n\n### Competing Interest Statement\n\nThe authors have declared no competing interest.\n\n### Funding Statement\n\nNational Major Science & Technology Project for Control and Prevention of Major Infectious Diseases in China; Guangdong Science and Technology Department ;Guangzhou Science, Technology and Innovation Commission\n\n### Author Declarations\n\nAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.\n\nYes\n\nAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.\n\nYes\n\nI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).\n\nYes\n\nI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.\n\nYes\n\ndata unavailable", "full_text_html_url": "https://www.medrxiv.org/content/10.1101/2020.02.22.20025460v2.full", "public_url": "https://www.medrxiv.org/content/10.1101/2020.02.22.20025460v2", "abstract_html_url": "https://www.medrxiv.org/content/10.1101/2020.02.22.20025460v2.abstract", "pdf_url": "https://www.medrxiv.org/content/medrxiv/early/2020/02/25/2020.02.22.20025460.full.pdf", "rights": "\u00a9 2020, Posted by Cold Spring Harbor Laboratory. The copyright holder for this pre-print is the author. All rights reserved. The material may not be redistributed, re-used or adapted without the author's permission.", "publisher": "Cold Spring Harbor Laboratory Press", "pisa": "medrxiv;2020.02.22.20025460v2", "access_rights": "restricted", "authors": ["Tieying Hou", "Weiqi Zeng", "Minling Yang", "Wenjing Chen", "Lili Ren", "Jingwen Ai", "Ji Wu", "Yalong Liao", "Xuejing Gou", "Yongjun Li", "Xiaorui Wang", "Hang Su", "Bing Gu", "Jianwei Wang", "Teng Xu"]}